Zydus Cadila Seeks Emergency Use Authorisation For Its Covid-19 Vaccine From DCGI
Zydus’ Covid-19 vaccine has been named ZyCOV-D and is the first plasmid DNA based vaccine in India. Read on.
Indian drugmaker Zydus Cadila has reportedly applied for an emergency use nod for its Covid-19 vaccine. The company applied to the Drugs Controller General of India (DCGI) for emergency use authorisation in order to launch their vaccine. It has been named ZyCOV-D and is the first plasmid DNA-based vaccine in India. Reports also claim that this vaccine has shown some ‘good results.’
According to reports, Zydus Cadila was supposed to apply for the emergy use authorisation last week. However, due to some reasons, it got delayed. Now, another vaccine is going to be an indigenously created vaccine that has applied for emergy use authorisation. Zydus Cadila has been working on this vaccine for some time. As per reports, using the same vaccine, trials for children are being conducted in the country. It could be a ‘good situation’ as soon as the vaccine is authorized for emergency use by the panel alongside other list of vaccines that are available in the country for Covid-19.
As per a leading daily, ZyCOV-D has been tested for the age group between 12 – 18 in India. As many as 1000 people were taken for the testing, and the results showed that the vaccine is ‘safe and very well tolerated.’ As per the daily, the tolerability was similar to the adult population of the country.
The daily also reported that Zydus is currently organising a new facility to manufacture its Covid-19 vaccines. It can produce as many as 1 crore vaccines. Once the vaccine is approved, the mass manufacturing can be done ‘aggressively within 45-60 days’